OnKure Therapeutics, Inc. OKUR Concurrent Financing Issuance Costs Paid By Reneo Prior To Merger
Concurrent Financing Issuance Costs Paid By Reneo Prior To Merger at other companies
Other financials
Where this comes from
Reported directly by OnKure Therapeutics, Inc. in its filing.
Tagged under the XBRL concept okur:ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger.
The official record: OnKure Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about OnKure Therapeutics, Inc.'s concurrent financing issuance costs paid by reneo prior to merger.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OnKure Therapeutics, Inc.'s concurrent financing issuance costs paid by reneo prior to merger?
- OnKure Therapeutics, Inc. (OKUR) reported concurrent financing issuance costs paid by reneo prior to merger of $22.25K in Q4 2024.
- What does concurrent financing issuance costs paid by reneo prior to merger mean?
- Financing-related issuance costs settled by a predecessor or merging entity prior to the completion of a merger. This reflects the historical cost burden associated with securing capital during the pre-merger phase.